Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Condition(s):Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Multiple MyelomaLast Updated:January 25, 2016Completed
Hide Studies Not Open or Pending
Condition(s):Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Multiple MyelomaLast Updated:January 25, 2016Completed
Condition(s):Multiple MyelomaLast Updated:January 27, 2023Terminated
Condition(s):Multiple Myeloma in RelapseLast Updated:July 31, 2015Terminated
Condition(s):Multiple MyelomaLast Updated:November 17, 2016Completed
Condition(s):Relapsed Multiple Myeloma; Refractory Multiple Myeloma; Waldenstrom MacroglobulinemiaLast Updated:August 2, 2013Completed
Condition(s):Multiple MyelomaLast Updated:April 7, 2016Withdrawn
Condition(s):Multiple MyelomaLast Updated:February 28, 2018Completed
Condition(s):Multiple MyelomaLast Updated:January 13, 2012Completed
Condition(s):Multiple MyelomaLast Updated:November 23, 2018Unknown status
Condition(s):Multiple MyelomaLast Updated:November 8, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.